Hikma Pharmaceuticals LLC

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 3 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Preclinical1

By Therapeutic Area

top 1

Oncology

1100%

R&D Momentum

18/100

Pipeline Velocity

0/100

Trial Completion Rate

91/100

Pipeline Concentration

100/100

Pipeline Freshness

72/100

Activity

Key Events

Jun 18, 2026FDAMS Contin — MS CONTIN

Dec 22, 2025FDAMS Contin — MS CONTIN

Apr 29, 2025TrialExtension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients

Oct 31, 2024FDAMS Contin — MS CONTIN

May 2, 2024TrialBioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)

Dec 15, 2023FDAMS Contin — MS CONTIN

Jan 20, 2023FDAVancocin — VANCOMYCIN HYDROCHLORIDE

Jan 20, 2023FDAVancocin Hydrochloride — VANCOMYCIN HYDROCHLORIDE

4 more events

Jul 20, 2022TrialEfficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia

Jan 19, 2022TrialSafety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt

Aug 26, 2021FDAVancocin — VANCOMYCIN

Aug 26, 2021FDAVancocin Hydrochloride — VANCOMYCIN

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

5 patent groups across drugs · Source: FDA Orange Book

DrugExpires

MS ContinAug 12, 2028 MS Contin2 patentsJul 1, 2033 MS Contin3 patentsMar 12, 2034 Vancocin14 patentsMar 13, 2035 AnectineNov 2, 2041

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Oncology

Myeloid Leukemia

Carcemia

Oncology

Myeloid Leukemia

CarcemiaPreclinical

Regulatory

Regulatory Timeline

20171 event

FDAMay 26

MS Contin — MS CONTIN

Application NDA019516

20186 events

FDASep 18

MS Contin — MS CONTIN

Application NDA019516

FDASep 18

MS Contin — MS CONTIN

Application NDA019516

FDAJul 10

Vancocin — VANCOMYCIN HYDROCHLORIDE

Application NDA209481 (NDA)

FDAJul 10

Vancocin Hydrochloride — VANCOMYCIN HYDROCHLORIDE

Application NDA209481 (NDA)

FDAJan 26

Vancocin — FIRVANQ KIT

Application NDA208910 (NDA)

FDAJan 26

Vancocin Hydrochloride — FIRVANQ KIT

Application NDA208910 (NDA)

20193 events

FDAOct 7

MS Contin — MS CONTIN

Application NDA019516

FDAFeb 15

Vancocin — TYZAVAN

Application NDA211962 (NDA)

FDAFeb 15

Vancocin Hydrochloride — TYZAVAN

Application NDA211962 (NDA)

20214 events

FDAAug 26

Vancocin — VANCOMYCIN

Application NDA213895 (NDA)

FDAAug 26

Vancocin Hydrochloride — VANCOMYCIN

Application NDA213895 (NDA)

FDAAug 20

Anectine — SUCCINYLCHOLINE CHLORIDE

Application NDA215143 (NDA)

FDAMar 4

MS Contin — MS CONTIN

Application NDA019516

20233 events

FDADec 15

MS Contin — MS CONTIN

Application NDA019516

FDAJan 20

Vancocin — VANCOMYCIN HYDROCHLORIDE

Application NDA210274 (NDA)

FDAJan 20

Vancocin Hydrochloride — VANCOMYCIN HYDROCHLORIDE

Application NDA210274 (NDA)

20241 event

FDAOct 31

MS Contin — MS CONTIN

Application NDA019516

20251 event

FDADec 22

MS Contin — MS CONTIN

Application NDA019516

20261 event

FDAJun 18

MS Contin — MS CONTIN

Application NDA019516

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)